Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India

Indian Journal of Sexually Transmitted Diseases

Volumn 31, Issue 1, 2010, Pages 30-34

  Patel, Atul K ^a   Patel, Ketan K ^a   Ranjan, Rajiv R ^a   Patel, Apurva R ^a   Patel, Jagdish K ^a  

^a Vedanta Institute of Medical Sciences   (India)

Author keywords

Antiretroviral therapy; nephrotoxicity; renal dysfunction; tenofovir

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CREATININE; EFAVIRENZ; INDINAVIR; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHOSPHORUS; POTASSIUM; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TENOFOVIR;

ADULT; AGED; ARTICLE; BACKACHE; BONE PAIN; CASE STUDY; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE COMPARISON; DRUG SAFETY; FANCONI RENOTUBULAR SYNDROME; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOPHOSPHATEMIA; INDIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MONITORING; NEPHROTOXICITY; PATIENT MONITORING; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; SIDE EFFECT; URINALYSIS; URINE; WALKING DIFFICULTY; WEAKNESS;

EID: 77956817906     PISSN: 02537184     EISSN: 19983816     Source Type: Journal    
DOI: 10.4103/0253-7184.68998     Document Type: Article

References (26)

1. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260
2. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004;292:191-201.
3. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years. AIDS 2007;21:1273-1281
4. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005;20:743-746
5. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis 2006;42:283-290
6. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004;18:960-963
7. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004;117:282-284
8. Rollot F, Nazal EM, Chauvelot-Moachon L, Kélaïdi C, Daniel N, Saba M, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: The role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003;37:e174-6.
9. Peyrière H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, et al. Renal tubular dysfunction associated with tenofovir therapy: Report of 7 cases. J Acquir Immune Defic Syndr 2004;35:269-273
10. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009;10:482-487
11. Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003;17:935-937
12. Szczech LA. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top HIV Med 2008;16:122-126
13. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virusinfected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-1073
14. Antoniou T, Raboud J, Chirhin S, Yoong D, Govan V, Gough K, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: A retrospective cohort study. HIV Med 2005;6:284-290
15. Gupta SK. Editorial comment: Tenofovir-related nephrotoxicity-who's at risk? AIDS Read 2007;17:102-103
16. Atta MG, Fine DM. Editorial comment: Tenofovir nephrotoxicity-the disconnect between clinical trials and real-world practice. AIDS Read 2009;19:118-119
17. Coca S, Perazella MA. Rapid communication: Acute renal failure associated with tenofovir: Evidence of drug-induced nephrotoxicity. Am J Med Sci 2002;324:342-344
18. Gupta SK. Tenofovir-associated Fanconi syndrome: Review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008;22:99-103.
19. Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez JC. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: A report of 3 cases. AIDS Read 2009;19:114-121
20. James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovirrelated nephrotoxicity: Case report and review of the literature. Pharmacotherapy 2004;24:415-418
21. Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: A cohort and case-control study. J Acquir Immune Defic Syndr 2004;37:1489-1495
22. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitorbased versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197:102-108
23. Buchacz K, Young B, Baker RK, Moorman A, Chmiel JS, Wood KC, et al. Renal function in patients receiving tenofovir with ritonavir/ lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort. J Acquir Immune Defic Syndr 2006;43:626-628
24. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:1559-1585
25. Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, Russ R, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 2009;89:513-519
26. Fine DM. Editorial comment: Tenofovir nephrotoxicity-vigilance required. AIDS Read 2005;15:362-363